In 2002, evidence of PD-1 pathway-mediated tumor immunity was first reported: after PD-1 binds to PD-L1, tumor cells used recognition of T-cell receptors to further suppress immunity and evade immune surveillance, and then significantly promoted tumorigenesis and invasion (Figure 1) (29). This evidence concerns the gene CD274 and neoplasm.